Using Genomics Approaches to Understand the Function of Oncogenic Fusion Transcription Factors
Dr.EMILY R. THEISEN
Assistant Professor Department of Pediatrics
The Ohio State University College of Medicine Columbus, OH
Center for Childhood Cancer and Blood Diseases
The Abigail Wexner Research Institute at Nationwide Children’s Hospital Columbus, OH
时 间: Nov. 4th (Thursday), 9:00 a.m.
地 点: Zoom
会议ID: 746 492 6744 (Password: 654321)
Dr. Zhi Qi, Peking-Tsinghua Center for Life Sciences & Center for Quantitative Biology
Many pediatric cancers are characterized by the expression of fusion oncogenic transcription factors. These tumors are often aggressive with few effective treatments and poor outcomes for those with metastatic, relapsed, and refractory disease. In the Theisen Lab, we seek touse genomics and proteomics techniques in parallel with molecular and chemical tools to better understand how these fusions function, with a focus on chimeric proteins containing an intrinsically disordered domain from either the EWSR1 or FUS protein. In Ewing sarcoma, we study EWS/FLI and have developed a uniquesuite of EWS and FLI mutants for functional studies. In the first part of my talk, I’ll discuss how application of new genomics techniques like CUT&RUN and CUT&Tag greatly enhanced our ability to assess the relationship between structure and function of both the EWS and FLI domains. In the second half of my talk, I’ll talk about my groups ongoing efforts to build on these techniques and use Ewing sarcoma as a model system define the enzymatic and nonenzymatic functions of the critical EWS/FLI co-regulator LSD1 and why this data is needed for the intelligent use of LSD1 inhibitors in the clinic.